Alimera Sciences (ALIM)
(Delayed Data from NSDQ)
$5.60 USD
+0.04 (0.72%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $5.60 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth B Momentum B VGM
Price, Consensus and EPS Surprise
ALIM 5.60 +0.04(0.72%)
Will ALIM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ALIM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALIM
Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
Alimera (ALIM) Rises on Merger Deal With ANI Pharmaceuticals
ALIM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates
New Strong Sell Stocks for March 13th
Alimera Sciences (ALIM) Reports Q4 Loss, Tops Revenue Estimates
Other News for ALIM
Catalyst Watch: Tesla deliveries, Constellation Brands earnings, and the June Jobs Report
Alimera Sciences just downgraded at Alliance Global Partners, here's why
Alimera Sciences just downgraded at Maxim, here's why
Hold Rating Maintained Amid ANI Pharmaceuticals Acquisition of Alimera Sciences
Alimera Sciences just downgraded at H.C. Wainwright, here's why